A Study to Evaluate the Effect of Bimekizumab on Gene Expression Biomarkers in Study Participants With Moderate to Severe Plaque Psoriasis

Recruiting

Phase 3

BimekizumabA Study to Evaluate the Effect of Bimekizumab on Gene Expression Biomarkers in Study Participants With Moderate to Severe Plaque Psoriasis

Sponsor:

UCB Biopharma SRL

Code:

NCT06506916

Conditions

Moderate to Severe Plaque Psoriasis

Psoriatic Arthritis

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Accepted

Interventions

bimekizumab

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-10-03. This information was provided to ClinicalTrials.gov by UCB Biopharma SRL on 2025-09-19.